Pop Quiz
Infection Risk Associated with Interclass Biologic Switching in Psoriasis Treatment
A systemic review and meta-analysis of interclass switching of biologic agents in psoriasis treatment found that risk of infection, particularly when transitioning from agents like anti−TNF-α to newer classes such as anti–IL-17A and anti–IL-17A/F. While switching biologics can improve therapeutic outcomes in psoriasis, it may also modulate the immune system in ways that predispose patients to certain infections. The review quantified this risk and highlighted specific patterns.